Abstract
OBJECTIVE: To determine the feasibility of a randomized controlled trial of the effect of a tai chi program on quality of life and exercise capacity in patients with COPD.
METHODS: We randomized 10 patients with moderate to severe COPD to 12 weeks of tai chi plus usual care (n = 5) or usual care alone (n = 5). The tai chi training consisted of a 1-hour class, twice weekly, that emphasized gentle movement, relaxation, meditation, and breathing techniques. Exploratory outcomes included disease-specific symptoms and quality-of-life, exercise capacity, pulmonary function tests, mood, and self-efficacy. We also conducted qualitative interviews to capture patient narratives regarding their experience with tai chi.
RESULTS: The patients were willing to be randomized. Among 4 of the 5 patients in the intervention group, adherence to the study protocol was excellent. The cohort's baseline mean ± SD age, percent-of-predicted FEV1, and ratio of FEV1 to forced vital capacity were 66 ± 6 y, 50 ± 12%, and 0.63 ± 0.14, respectively. At 12 weeks there was significant improvement in Chronic Respiratory Questionnaire score among the tai chi participants (1.4 ± 1.1), compared to the usual-care group (−0.1 ± 0.4) (P = .03). There were nonsignificant trends toward improvement in 6-min walk distance (55 ± 47 vs –13 ± 64 m, P = .09), Center for Epidemiologic Studies Depression Scale (−9.0 ± 9.1 vs −2.8 ± 4.3, P = .20), and University of California, San Diego Shortness of Breath score (−7.8 ± 3.5 vs −1.2 ± 11, P = .40). There were no significant changes in either group's peak oxygen uptake.
CONCLUSIONS: A randomized controlled trial of tai chi is feasible in patients with moderate to severe COPD. Tai chi exercise as an adjunct to standard care warrants further investigation. (ClinicalTrials.gov registration NCT01007903)
- tai chi
- quality of life
- exercise capacity
- chronic obstructive pulmonary disease
- COPD
- patient narratives
- depression
Footnotes
- Correspondence: Gloria Y Yeh MD MPH, Division for Research and Education in Complementary and Integrative Medical Therapies, Osher Research Center, Harvard Medical School, 401 Park Drive, Suite 22A, Boston MA 02215. E-mail: gyeh{at}hms.harvard.edu.
This study was supported by an award (K24 AT00589, to Dr Phillips) from the National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM), and by Beth Israel Deaconess Medical Center General Clinical Research Center grant RR 01032. Dr Yeh was supported by NIH NCCAM career-investigator award K23AT002624. Dr Wayne was supported by NIH NCCAM grant U19 AT002022. Dr Roberts has disclosed a relationship with Gilead Pharmaceuticals. The other authors have disclosed no conflicts of interest.
- Copyright © 2010 by Daedalus Enterprises Inc.